Israeli device company Inspiro Medical has announced that a safety and efficacy study of formoterol delivered by the Inspiromatic dry powder inhaler for the treatment of asthma in children met both its primary and secondary endpoints. According to the company, the randomized, crossover, double blind study, which involved 30 asthmatic children, demonstrated statistically significant improvement in FEV1 after dosing, and even patients with poor inhalation technique were able to inhale effective doses of the medication.
The Inspiromatic is a breath-synchronized active device that the company says “works with extremely low inhalation flow rates and assures optimal drug delivery by providing the appropriate powder quantity, at an optimal flow, at the right time.”
Inspiro CEO Nimrod Kaufmann commented, “I’m very happy with the study results showing that the Inspiromatic achieved safety and efficacy. This successful study will enable us to move to the next step in the company development and partner with pharmaceutical companies to develop drug-device combinations and also bring better therapy to patients with poor inhalation technique.”
The company says that it will open an investment round in the third quarter of 2013 to fund further development of the device.
Read the Inspiro press release.
